Dr. Logsdon’s expertise to help guide the company’s further research and development for its patented drug-delivery technology.
To be led by accomplished Neurosurgeon Dr. Julian Bailes, the Medical Advisory Board will support the Company in developing breakthrough psychedelic medicine technologies for mental health treatments…
Chief Visionary Officer of Psycheceutical, Zappy Zapolin, will join other prominent leaders in Psychedelics on Benzinga’s Council Board.
Vici Health Sciences CEO Anish Dhanarajan to join Psycheceutical as Research and Development Advisor.
Famed entrepreneur excited about the company’s development of psychedelic pharmaceutical medicines to treat the widespread mental health crisis.
Psycheceutical Chief Visionary Officer, Zappy Zapolin, will be a featured presenter at the esteemed Legacy Investment Summit 2022, to be held at the Mandarin Oriental Hotel in Washington, D.C. on March 31 and April 1.
Psycheceutical, Inc. has announced it has entered into a strategic agreement with Vici Health Sciences, known for providing pharmaceutical clients with tools to innovate and grow through new product development. Through this relationship, Psycheceutical will be able to test and develop its patented technologies and continue its focus on exploring the formulation of unique, branded compounds.
Esteemed neurosurgeon to participate in strategy, direction for development of novel psychedelic therapy innovations.
Psycheceutical, Inc., today announced the company has been fully acquired by Blue Water Ventures International, Inc. (OTCPK: BWVI).
